8th Global Symposium on Ketogenic Therapies

第八届全球生酮疗法研讨会

• 批准号: 10753748
• 负责人: Jong Min Rho
• 金额: $ 2.5万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-08-01 至 2024-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10753748
• 关键词: Adult; Advocacy; Alzheimer' s Disease; Anniversary; Anticonvulsants; Anxiety; Awareness; Basic Science; Bipolar Disorder; Brain; Budgets; California; Carbohydrates; Clinical; Clinical Investigator; Clinical Research; Cognition Disorders; Collaborations; Communities; Congresses; Country; Dedications; Diet and Nutrition; Diet therapy; Dietitian; Discipline; Disease; Dissemination and Implementation; Eastern Africa; Eastern Europe; Education; Educational workshop; Effectiveness; Eligibility Determination; Epilepsy; Fasting; Fatty Acids; Fatty acid glycerol esters; Fellowship; Fertilization; Formulation; Foundations; Funding; Future Generations; Glucose Transporter; Goals; Grant; Growth; Headache; International; Intractable Epilepsy; Ketone Bodies; Knowledge; Lead; Malignant - descriptor; Malignant neoplasm of brain; Mediator; Medical; Mental Depression; Mental Health; Mental disorders; Metabolic; Metabolism; Modernization; Multiple Sclerosis; Neurologic; Nurses; Parkinson Disease; Patients; Perception; Physicians; Postdoctoral Fellow; Pre-Clinical Model; Professional Organizations; Property; Proteins; Protocols documentation; Randomized; Recording of previous events; Research; Research Personnel; Resources; SLC2A1 gene; Schedule; Schizophrenia; Science; Scientist; Series; Sleep Disorders; Social Workers; Societies; Solid; Southeastern Asia; Standardization; Students; Syndrome; Therapeutic; Time; Training; Translational Research; Travel; United States National Institutes of Health; Variant; autism spectrum disorder; brain metabolism; chronic pain; clinical application; clinical efficacy; dietary; equity, diversity, and inclusion; experience; health application; innovation; interdisciplinary collaboration; interest; ketogenic diet; ketogentic; meetings; neglect; nervous system disorder; neuroprotection; novel; personalized care; posters; pre-clinical; programs; prospective; spinal cord and brain injury; success; symposium; treatment choice

PROJECT SUMMARY The ketogenic diet (KD) is an established medical therapy for drug-resistant epilepsy, and since its origins in 1921 has steadily grown in clinical importance and worldwide implementation. Moreover, the expanding research into the scientific underpinnings of this metabolism-based treatment have highlighted numerous novel mechanisms. Moreover, there is mounting experimental evidence for potential disease-modifying and neuroprotective properties of metabolic substrates such as ketone bodies and fatty acids, such that preclinical and clinical investigators have been exploring broader uses of the KD and its variants in diverse neurological (and even mental health) conditions such as malignant brain cancer, autism spectrum disorder, Alzheimer's disease, and bipolar disorder. Despite proven clinical efficacy and relative affordability compared to anti-seizure medications, large regions of the world still do not and cannot broadly offer KD therapies to eligible patients. Centers often have inadequate resources, as well as a lack of appropriately trained physicians and/or dietitians. Furthermore, the latest research findings may not be well disseminated, and a lack of standardized protocols and management strategies present additional barriers. Without adequate support or proper education, patients may not consider this treatment due to its traditional restrictiveness and myths surrounding its use. Regular regional and international meetings are needed where scientists, physicians, dietitians, nurses, social workers and trainees at all levels can meet and discuss and share protocols, research innovations, clinical experience and establish new collaborations in the growing KD field. The 8th Global Symposium on Ketogenic Therapies (to be held September 17-21, 2023 in San Diego, California) is the latest in a successful and evolving biennial conference series first launched in 2008 with support from a NIH R13 conference grant. There has been an enduring collaborative spirit with a common purpose that has now matured into a new professional society called the International Neurological Ketogenic Society or INKS. The 8th Global Symposium represents another leap forward: the focus remains on promoting collaborative interactions among clinical and basic scientists and trainees and disseminating the latest research to the community and beyond, and a strong emphasis will be placed on standardizing and enhancing international dissemination and implementation – all of this in the spirit of equity, diversity and inclusion. Moreover, this will be the first congress in the biennial series organized in conjunction with two aligned organizations, the Glucose Transporter Deficiency 1 (GLUT1) Foundation and the International Society of Neurogastronomy (ISN). The KD is the treatment of choice for the GLUT1 deficiency syndrome, and ISN's focus on the science and practice of flavor perception represents an often-neglected aspect of diet and nutrition that is central to compliance and success of dietary treatments. These symposia will remain the definitive venue for progress in and advocacy for metabolism-based therapies for neurological disorders.

项目摘要 生酮饮食（KD）是一种治疗耐药性癫痫的既定医学疗法，自2004年起， 1921在临床重要性和全球实施方面稳步增长。此外，不断扩大的研究 这种基于代谢的治疗的科学基础，突出了许多新的 机制等此外，有越来越多的实验证据表明， 代谢底物如酮体和脂肪酸的神经保护特性， 临床研究人员一直在探索KD及其变体在各种神经系统疾病中的更广泛用途。 (and甚至是精神健康），如恶性脑癌，自闭症谱系障碍，阿尔茨海默氏症 疾病和躁郁症。尽管与抗癫痫药物相比， 尽管目前的药物治疗已经取得了进展，但世界上大部分地区仍然没有也不能广泛地为符合条件的患者提供KD治疗。 这些中心往往资源不足，缺乏经过适当培训的医生和/或营养师。 此外，最新的研究结果可能无法很好地传播，并且缺乏标准化的协议 和管理策略带来了额外的障碍。如果没有足够的支持或适当的教育， 由于其传统的限制性和围绕其使用的神话，可能不会考虑这种治疗。定期 需要召开区域和国际会议，科学家、医生、营养师、护士、社会工作者 各级学员可以见面，讨论和分享协议，研究创新，临床经验， 并在不断发展的KD领域建立新的合作关系。第八届生酮治疗全球研讨会（至 将于2023年9月17日至21日在加州圣地亚哥举行）是一个成功和不断发展的两年一度的最新成果 会议系列于2008年首次推出，得到了NIH R13会议资助的支持。出现了 具有共同目标的持久合作精神，现已成熟为一个新的专业社会， 国际神经生酮学会或INKS。第八届全球研讨会代表了另一个飞跃 展望：重点仍然是促进临床和基础科学家之间的合作互动 和学员和传播最新的研究，以社区和超越，并大力强调 将把重点放在标准化和加强国际传播和实施-所有这一切 本着公平、多样性和包容的精神。此外，这将是两年一次的大会系列中的第一次大会 葡萄糖转运蛋白缺乏症1（GLUT 1） 基金会和国际神经美食学会（ISN）。KD是治疗的选择， GLUT 1缺乏综合征，以及ISN对风味感知的科学和实践的关注，代表了一种 饮食和营养的一个经常被忽视的方面，这是饮食治疗的依从性和成功的核心。这些 研讨会将仍然是促进和倡导代谢疗法的最终场所， 神经系统疾病